Combined TGE-SGE Expression of Novel PAI-1-Resistant t-PA in CHO DG44 Cells Using Orbitally Shaking Disposable Bioreactors
2011
Davami, Fatemeh, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran | Barkhordari, Farzaneh, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran | Alebouyeh, Mahmoud, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran | Adeli, Ahmad, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran | Mahboudi, Fereidoun, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
An important modification of thrombolytic agents is resistance to plasminogen activator inhibitor-1 (PAI-1). In previous studies, a new truncated PAI-1-resistant variant was developed based on deletion of the first three domains in t-PA and the substitution of KHRR 128-131 amino acids with AAAA in the truncated t-PA. The novel variant expressed in a static culture system of Chinese Hamster Ovary (CHO) DG44 cells exhibited a higher resistance to PAI-1 when compared with the full-length commercial drug; Actylase. In the present study, the truncatedmutant protein was expressed in CHO DG44 cells in 50 ml orbital shaking bioreactors. The final yield of the truncated-mutant in the culture was 752 IU/ml, representing a 63% increase compared with the static culture system. Therefore, these results suggest that using the combined features of a transient and stable expression system is feasible for the production of novel recombinant proteins in the quantities needed for preclinical studies.
显示更多 [+] 显示较少 [-]